Member Info for Laura2022

Highest bid price for 4 weeks

Up again on no visible buys

Must be

A) delayed

B) market senses news

£10k buy at virtually 7.9p

Expecting more

Offering above bid again for over 300k

Invoiced sales in April 2026 were 3x those achieved in September 2025.

• First phase of contract with UK Public Sector Space Client delivered successfully, with exceptional customer feedback and current commercial discussions over a potential second phase.

• Substantial progress made towards a major framework agreement with a top-seven prime contractor to MoD, now in the final stages of commercial approvals.

• Strong commercial execution driving results, with eight new clients (including two top-six prime contractors to MoD), a further Prime framework on track, and a c.2.5x uplift in win rate.

• The Board remains encouraged by long-term UK defence spending trajectory, with spending projected to reach 2.5% of GDP by 2027.

Tick up now

Expecting large MOD contracts

Block buyer is indeed back

All shown as sells

200, 250, 400ks

Holdit

Something must be in ether as on very quiet few days on Aim they are bidding 3.62p for over 200,000

I agree, we need to know who this strategic investor is

BD

I agree, added what little I could 1.8p before went to NT

The 7.62, 7.7p stock from last week has gone

Now paying 7 76p

Think the block buyer will be back today

Charts extremely, extremely oversold and base formed at 3p

The interview also explored the broader UK defence spending environment and how RC Fornax is positioning itself to benefit from existing Ministry of Defence budgets as well as future investment plans. Shepherd estimated there is a £1 billion to £1.5 billion addressable market opportunity for the company within current defence spending levels

Bigsid

He's been here 5yrs+ and a complete waste of energy

Hence filtering

Wigwammer

Absolutely.. and people need to remember the AIM market and certainly life sciences suffered from a lack of liquidity, investment and appetite for much of 2022-early 2025

So the funding by Lanstead has to be seen as a positive in that context

Its not easy getting key assets over the line

Look at last 5yrs for SAR HEMO SCLP to name but a few

If you believe it will come for IMM in 2026 then buy /hold

If not there are 100s of pver investments out there

Its that simple

Best wishes

This is highly unusual to only have the CEO recommending the deal ( see the GM circular on website ) and no otjer "irrevocable undertakings " support from ANY major holders

So far, albeit only 3 days, there have been no large delayed funds belonging out or TR1s

I think someone WILL buy it

The IP has to be worth £10mln-20mln +then the cash of £10mln + £1mln for market listing

Versus £5mln cap

Could they be one of the parties (plural)

P140 partnering discussions

As reiterated in recent announcements, P140 remains a core value driver for ImmuPharma. The Company continues to progress discussions with a number of potential partners, including under signed confidentiality agreements. The management team also attended the Bio-Europe Spring healthcare event in Lisbon this week, where a number of meetings were held in relation to P140. ImmuPharma remains focused on completing a value‑enhancing licensing deal in 2026.

Thanks ogm4

May 29, 2026     

For decades, treating autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis has followed a familiar pattern of cycling through therapies to manage symptoms while leaving the underlying drivers of disease unresolved. Here our goal is shifting toward something different: addressing the B cells and T cells that help sustain autoimmune disease and dysregulated immune responses. This approach is known as immune reset.

The goal is not just to manage signs and symptoms of disease — it’s to fundamentally change its course for patients.

Mary Struthers, scientific vice president in immunology, and Tim Campbell, vice president of hematology and cell therapy early clinical development, discuss how immune reset may shape the future of autoimmune disease treatment.

 

What is immune reset and why is it important in treating autoimmune diseases?

 

Bently.

Clearly that was in direct response to the trolls whom were reported to the company and FCA

CLEAR AS DAY

Fully funded

And still no TR1s ( up or down )

Latest time and date for receipt of Forms of Proxy or electronic

proxy appointments for the General Meeting

10.30 a.m. on 17 June 2026

General Meeting to approve the Proposals 10.30 a.m. on 19 June 2026